Management of Medullary Thyroid Cancer.

Management of Medullary Thyroid Cancer. Endocrinol Metab Clin North Am. 2019 Mar;48(1):285-301 Authors: Viola D, Elisei R Abstract Medullary thyroid cancer (MTC) is rare but aggressive. It can be cured only if intrathyroid at diagnosis. MTC can be sporadic (75%) or familial (25%) and the 2 forms are distinguished by RET mutations analysis. Calcitonin is the specific serum marker; its doubling time is the most important prognostic factor for survival and progression; 30% of MTC patients have distant metastases at diagnosis and, when progressing, systemic therapy with vandetanib or cabozantinib should be considered. Before starting this treatment, the possibility of using a local treatment should be evaluated to delay systemic therapy. A multidisciplinary team should care for these patients. PMID: 30717909 [PubMed - in process]
Source: The Medical Clinics of North America - Category: General Medicine Authors: Tags: Endocrinol Metab Clin North Am Source Type: research